Related Experiment Video
Updated: May 16, 2026
09:04
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
PPAR-γ -- a possible drug target for complicated pregnancies
Fergus P McCarthy1, Aoife C Delany, Louise C Kenny
1Department of Obstetrics & Gynaecology, Anu Research Centre, University College Cork, Cork, Ireland.
British Journal of Pharmacology
|November 29, 2012
Summary
Peroxisome proliferator activated receptors-gamma (PPAR-γ) are crucial for healthy pregnancy and placental development. Altered PPAR-γ expression is linked to pregnancy complications, suggesting its therapeutic potential.
Area of Science:
- Reproductive biology
- Molecular endocrinology
- Genetics
Background:
- Peroxisome proliferator activated receptors (PPARs) are ligand-activated transcription factors.
- PPARs are expressed in trophoblasts and regulate cell differentiation and proliferation.
- PPAR-β and PPAR-γ play integral roles in placentation and trophoblast differentiation.
Purpose of the Study:
- To review the role of PPAR-γ in normal pregnancy.
- To assess PPAR-γ's involvement in pregnancy complications.
- To explore PPAR-γ as a potential therapeutic target for adverse pregnancy outcomes.
Main Methods:
- Literature review
- Synthesis of existing research on PPAR-γ and pregnancy
Main Results:
- PPAR-γ regulates trophoblast differentiation and is vital for normal pregnancy.
- Altered PPAR-γ expression is associated with intrauterine growth restriction, preterm birth, pre-eclampsia, and gestational diabetes.
- Evidence suggests PPAR-γ's pivotal role in healthy pregnancy progression.
Conclusions:
- PPAR-γ is essential for normal pregnancy and placental function.
- Dysregulation of PPAR-γ is implicated in various pregnancy complications.
- PPAR-γ represents a promising therapeutic target for preventing and treating adverse pregnancy outcomes.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:15G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...